



Ami Organics Limited

CIN No. : L24100GJ2007PLC051093

Registered Office :- Plot No. 440/4, 5 & 6, Road No. 82/A, G.I.D.C. Sachin, Surat - 394230, Dist. Surat, Gujarat, India.

September 15, 2023

To,
The Listing Department,
BSE LIMITED,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort
Mumbai- 400 001

To,
The Listing Department
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor, Plot No. C-1,
G-Block, Bandra Kurla Complex,
Mumbai -400051

Scrip Code: 543349

NSE Symbol : AMIORG

Subject: Press Release pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

In accordance with Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a Press Release dated September 15, 2023 for dissemination.

This Press Release will be available on the website of the Company www.amiorganics.com.

Kindly take the same on record.

Yours faithfully,
For, AMI ORGANICS LIMITED



Ekta Kumari Srivastava
Company Secretary & Compliance Officer

Encl: Press Release



Info@amiorganics.com



www.amiorganics.com



+91 72279 77744 / 75730 15366



AMI ORGANICS LIMITED

Ami Organics and Fermion ink another Multi-Year, Multi-Tonne, Multi-Million Dollar agreement for Additional Advanced Pharmaceutical Intermediate

Surat, September 15, 2023: Ami Organics Limited (BSE: 543349, NSE: AMIORG) a leading global manufacturer of advanced pharmaceutical intermediates and speciality chemicals, has signed another definitive multi-year, multi-tonne agreement with Fermion, a fully owned subsidiary of Orion Corporation, Finland. As part of the agreement, Ami Organics will supply an additional advanced pharmaceutical intermediate to Fermion.

Based on the supply projection shared by Fermion, the total minimum contract value is expected to be multi-million Dollar, spread across multi-year horizon. The product is expected to start contributing meaningfully to the revenue from FY25.

Ami Organics had signed its first agreement with Fermion in November 2022 for supply of an advanced pharmaceutical intermediate. This agreement is in addition to previous agreement and further increases the total value of the CDMO contract with Fermion.

Commenting on development, Mr. Naresh Patel, Executive Chairman & Managing Director, Ami Organics Limited, said: *"I am delighted to extend this partnership with Fermion, appreciating the confidence they have placed in our dedication and excellence. This new agreement marks a significant stride forward in our collaboration. Our ongoing discussions with all our customers centre around delivering more value-added products and this agreement is testimony to our shared objectives. I am confident that we will continue to have quality dialogue with Fermion and other valued customers, paving the way for further opportunities to strengthen our relationships in the future"*

ABOUT AMI ORGANICS LIMITED:

Ami Organics, headquartered at Surat, is a R&D driven manufacturer of specialty chemicals with varied end usage, focussed on the development and manufacturing of advanced pharmaceutical intermediates ("Pharma Intermediates") for regulated markets and generic active pharmaceutical ingredients ("APIs") and New Chemical Entities ("NCE") and key starting material for agrochemical and fine chemicals. Ami Organics has developed and commercialised over 520+ Pharma Intermediates for APIs across 23 key therapeutic areas since inception and NCE, with a strong focus on R&D across select high-growth high margin chronic therapeutic areas.

ABOUT FERMION:

Fermion is a Finnish manufacturer of active pharmaceutical ingredients (APIs) and part of Orion Group. Fermion develops and manufactures APIs for Orion. Fermion also develops, manufactures and markets APIs to companies in global generic market as well as under exclusive contracts to companies focusing on new chemical entities (NCEs).

PRESS RELEASE

For Immediate dissemination



AMI ORGANICS LIMITED

CAUTIONARY STATEMENT:

This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward-looking statements. No warranties or representations are made as to the accuracy, achievement, or reasonableness of such statements, estimates or projections, and Ami Organics has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.

For details, please contact:

<p>Investor Relations at Ami Organics Ekta Srivastava, Company Secretary & Compliance Officer cs@amiorganics.com</p> <p>Ernst & Young Mr. Rahul Thakur rahul.thakur@in.ey.com</p>	<p>Registered Office Plot no. 440/4, 5 & 6, Road No. 82/A, GIDC Sachin, Surat- 394230 CIN: L24100GJ2007PLC051093 ISIN: INE00FF01017 NSE Code: AMIORG BSE CODE: 543349 Website: www.amiorganics.com</p>
---	--